Catalent Financials

Catalent Stock Summary

Catalent competes with IQVIA Holdings, West Pharmaceutical, Charles River, Bio Rad, and Teleflex Incorporated. Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 19000 people.

Catalent Key Financial Ratios

Catalent Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Catalent's current stock value. Our valuation model uses many indicators to compare Catalent value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catalent competition to find correlations between indicators driving Catalent's intrinsic value. More Info.Catalent is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Catalent by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.